Podcasts about neuro oncology

In today's episode, supported by Chimerix, we spoke with Patrick Y. Wen, MD, about the FDA approval of dordaviprone (Modeyso) for the treatment of adult and pediatric patients at least 1 year of age with H3K27M-mutated diffuse midline glioma who have progressive disease following prior therapy. Dr Wen is the director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute; as well as a professor of neurology at Harvard Medical School in Boston, Massachusetts. In our conversation, Dr Wen discussed the significance of this accelerated approval across patient age groups, key efficacy and safety data that supported this approval, and the importance of biomarker testing in patients with glioma. He also highlighted potential next steps for expanding the investigation of dordaviprone in patients with glioma and emphasized the ways that multidisciplinary collaboration can provide patients with personalized, optimized care. 

Dr. Maya Graham interviews Dr. Jessica Foster about her and her team's recent manuscript, entitled "Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models". This work was published online in Neuro-Oncology in May 2025.

Welcome to another powerful episode of the Game Over: c*ncer podcast by Cannonball Kids' cancer Foundation (CKc)!In this conversation, hosts Dana and Val sit down with Dr. Cassie Kline, attending physician and Director of Clinical Research in the Department of Neuro-Oncology at Children's Hospital of Philadelphia.Dr. Kline shares her journey into pediatric oncology, her personal connection to cancer research, and her role in advancing innovative treatments for children with brain and spinal cord tumors. From her early days as CKc's first Young Investigator to serving on CKc's Scientific Advisory Board, Dr. Kline's story highlights the critical impact of research funding, mentorship, and collaboration in creating real hope for families.You'll hear insights on:The challenges young investigators face and why early funding is crucialHow clinical trials and immunotherapy are changing the future of pediatric brain tumor careThe role of CKc's Scientific Advisory Board in ensuring the most innovative research is fundedDr. Kline's perspective as a woman in STEM and the importance of diversity in medicineThis episode is a must-listen for anyone passionate about pediatric cancer research, advocacy, and the fight to deliver better treatment options for kids.Tune in to hear this inspiring and informative conversation. Don't forget to subscribe, leave a review, and join the fight to make Game Over: c*ncer a reality.Connect with our Guest Dr. Cassie Kline:  https://www.chop.edu/doctors/kline-cassieConnect with Dana: https://www.linkedin.com/in/danaknichols/Connect with Val: https://www.linkedin.com/in/valerie-solomon/Upcoming Ckc Events: https://cannonballkidscancer.org/category/make-an-impact/events/----------------------------------Podcast Produced by Hi Hello Labs: Website: https://www.hihellolabs.com/

Neuro-Oncology: Breakthroughs & Treatment Strategy with guest Dr. Sylvia Kurz July 20, 2025 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Dr. Evan Noch interviews Dr. Akshitkumar Mistry about his and his team's recent manuscript entitled "A clinically annotated transcriptomic atlas of nervous system tumors", published online in Neuro-Oncology in May 2025 Link to the paper: https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf130/8151442

Do you know anyone with dementia? If you don't, you will. We humans are living longer and healthier lives. There are more healthy 75 year old people alive now than there ever have been. However, the number of people with dementia is sky rocketing as well. Enter Dr. Mechtler…Dr. Lazslo Mechtler is the Medical Director of Dent Neurologic Institute, the Chief of Neuro-Oncology at Roswell Park Cancer Institute and is also the Director of the DENT Headache Center, Neuro-Oncology Center, and Cannabis Clinic.Dr. Mechtler gives us a fantastic review of dementia, and Alzheimer's disease. Then he talks about the work they are doing at the DENT Institute to treat dementia with cannabinoids.DENT Neurologic Institute - Cannabis Clinic - WebsiteLazlo Mechtler - LinkedInLazlo Mechtler - DENT-website profileMusic by:Christopher Cros - Sailing -YouTubeAdditional Music:Desiree Dorion desireedorion.comMarc Clement - FacebookTranscripts, papers and so much more at: reefermed.ca

Dr. Iyad Alnahhas interviews Drs. Isaias Hernandez-Verdin and Agusti Alentorn about their recent manuscript entitled: "Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: An ancillary study from the BLOCAGE trial", published online in Neuro-Oncology in March 2025   Link: https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf059/8058778

Dr. Evan Noch interviews Dr. Marion Mateos about her and her team's recent manuscript entitled: "Germline analysis of an international cohort of pediatric diffuse midline glioma patients", published online in Neuro-Oncology in March 2025.

Send us a textIn this episode, we sit down with Trishla to explore the world of neuro-oncology research. Trishla shares how meaningful moments shaped her passion for clinical trials and patient care. We discuss the challenges around access, the need for more research in brain cancer, and the options available to patients and families. Support the showRare Enough is a podcast powered by Head for the Cure, sharing real stories of resilience, hope, and community from those facing brain tumors and the people who walk beside them. Subscribe, listen, and share, because every story matters, and no one should face brain cancer alone. Follow on Instagram @RareEnoughPodcast Learn more at BrainsfortheCure.org

Dr. Iyad Alnahhas interviews Drs. Cynthia Hawkins and Arun Vadivel about their recent manuscript entitled: "The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases", published online in Neuro-Oncology in February 2025.   More Information

Compassion and creativity are vitally important these days in cancer care. The old rule of thumb, especially in brain cancer, of standard of care just isn't enough anymore. Patients and families need a voice, and need to know that they are heard when asking questions about clinical trials, supplements, holistic options, and cross-collaboration across neuro-oncology care. Enter Dr.'s Soma Sengupta and Dominique Higgins of UNC School of Medicine in North Carolina. On today's episode (in total the 49th episode for Game On Glio), kicking off brain cancer awareness month, I sit down with them to discuss the crucial need for elevating patient voices, the importance of clinical trials like IGV-001, out of the box treatments (like GammaTile), and the novel way the doctors at UNC are helping patients reach new heights in their care.   Listen now or watch the full video episode on YouTube. Thank you so much for making Game On Glio a top 10 podcast nationally! Welcome to Season 5.   Season Sponsors: GammaTile Therapy Imvax Inc.   Episode Sponsor: Plus Therapeutics

Dr. Iyad Alnahhas interviews Dr. Peter LaViolette about his and his team's recent manuscript entitled: "Multi-Site Retrospective Analysis of Diffusion and Perfusion MRI Correlates to Glioma Characteristics Derived from Radio-Pathomic Maps", published online in Neuro-Oncology in February 2025.

Send us a textDr. Ashley Aaroe joins us today to talk all about Neuro-oncology, from brain tumor classification, to complications of chemotherapy and immunotherapy, to the importance of patient advocacy.Find her on X/Twitter.  Check out our website at www.theneurotransmitters.com to sign up for emails, classes, and quizzes! Would you like to be a guest or suggest a topic? Email us at contact@theneurotransmitters.com Follow our podcast channel on

Description: Dr. Evan Noch interviews Drs. Cecile Riviere-Cazaux and Terry Burns about their recent manuscript entitled: "A field resource for the glioma cerebrospinal fluid proteome: impacts of resection and location on biomarker discovery", published online in Neuro-Oncology in December 2024.   Link: https://doi.org/10.1093/neuonc/noae277  

Israel Gasperin is a visionary entrepreneur, engineering scientist and the founder of Zentrela, a company dedicated to transforming cannabis research through advanced neurotechnology and AI. Under Israel's leadership, Zentrela developed the Psychoactive Effect Level (PEL) metric, an innovative EEG-based measure capable of objectively assessing cannabis products' psychoactive potency. By combining wearable EEG technology with AI-driven EEG analysis, the PEL metric provides cannabis producers, researchers, and regulators with a non-invasive and cost-effective way to quantify product effects and maintain quality control.  At CannMed 25, Israel will share results from over 10,000 EEG scans of consumers using a wide range of cannabis products in his oral presentation titled “Cannabis Effect Research Driven by EEG Technology and Machine Learning”. During our conversation, we discuss:  How Zentrela's wearable EEG technology got its start measuring drowsiness in truck drivers   The unreliability of consumer feedback with regards to cannabis product effects  How the PEL metric was created to measure the unique psychoactive effects of cannabis How producers can use PEL to objectively measure the quality and effectiveness of cannabis products beyond cannabinoid percentages  Research findings that show THC% and PEL% are not directly correlated  and more  Thanks to This Episode's Sponsor: The DENT Institute With more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson's, Dementia, and Neuro-Oncology. With their mission of advancing neuroscience, the Dent Institute established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout the institute. Learn more at dentinstitute.com Additional Resources Zentrela Website Israel Gasperin on LinkedIn Use of a Novel EEG-Based Objective Test, the Cognalyzer®, in Quantifying the Strength and Determining the Action Time of Cannabis Psychoactive Effects and Factors that May Influence Them Within an Observational Study Framework Sensitivity, Specificity and Accuracy of a Novel EEG-Based Objective Test, the Cognalyzer®, in Detecting Cannabis Psychoactive Effects Register for CannMed 25 Meet the CannMed 25 Speakers and Poster Presenters Review the Podcast CannMed Archive

Description: Dr. Ankush Bhatia interviews Drs. Macarena de la Fuente and Mehdi Touat about their recent manuscript entitled: "The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma" published online in Neuro-Oncology in December 2024.   Link: https://doi.org/10.1093/neuonc/noae259

Dr. Iyad Alnahhas interviews Dr. Craig Horbinski about his and his team's recent manuscript entitled "The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastoma", published online in Neuro-Oncology in December 2024.

Dr. Iyad Alnahhas interviews Dr. Nathalie Albert about her and her team's recent manuscript entitled: "Measurable disease as baseline criterion for response in glioblastoma: A comparison of PET-based (PET RANO 1.0) and MRI-based (RANO) assessments", published online in Neuro-Oncology in January 2025.

Send us a textIn this episode we welcome Dr. Na Tosha Gatson, Director of Neuro-Oncology & Professor of Neurology and Medicine at IU Health. A leader in the field, Dr. Gatson shares insights on advancements in neuro-oncology, the impact of brain tumors on women's health, addressing health disparities, and the importance of quality-of-life care. Support the show

In a conversation with CancerNetwork®, Shewetal Mehta, PhD, spoke about her research team's focuses in moving novel brain cancer therapies down the pipeline as part of an early phase clinical trials program at the Ivy Brain Tumor Center. Mehta, the deputy director and pre-clinical core leader at the Ivy Brain Tumor Center of Barrow Neurological Institute in Phoenix, Arizona, underscored a scientifically rigorous, patient-driven philosophy that drives her team members to deliver timely answers to those with brain cancer via work in a clinical lab and a pre-clinical arm. This collaboration helps identify therapeutic agents that may demonstrate activity in the brain while determining patient populations who are suitable to enroll on clinical trials. As part of her institution's early phase trial program, Mehta specifically highlighted work associated with a phase 0/1 clinical trial (NCT06072586) evaluating BDTX-1535, a brain-penetrant fourth-generation EGFR inhibitor, for those with recurrent high-grade glioma harboring oncogenic EGFR alterations or fusions.1 Investigators are incorporating liquid biopsy, sampling cerebrospinal fluid from patients on treatment to monitor potential evolutions or changes in brain tumors. Regarding biomarker testing, Mehta described the roles that gene sequencing and immunohistochemistry can play in identifying targetable alterations in patients with brain cancer. She mentioned vorasidenib (Voranigo), which received approval from the FDA in August 2024, as an example of a targeted therapy that may be suitable for use in patients who are found to have actionable IDH mutations. “Over the last year, we've seen that we were capable of not just doing these early phase clinical trials [but of entering] this phase of moving drugs into phase 3 [studies]. That's exciting,” Mehta stated regarding her outlook on the current state of brain cancer treatment. “Right now, we are excited about these new classes of agents that are within the space, like the proteolysis targeting chimeras, protein degraders, and antibody-drug conjugates, which have shown amazing promise in the rest of the oncology space.” References 1.        Study of BDTX-1535 in recurrent high-grade glioma (HGG) participants with EGFR alterations or fusions. ClinicalTrials.gov. Updated January 15, 2025. Accessed January 15, 2025. https://tinyurl.com/m6kwr2b3 2.        FDA approves vorasidenib for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. News release. FDA. August 6, 2024. Accessed January 20, 2025. https://tinyurl.com/25r9fkvy

Drs Camidge and Boire discuss Dr Boire's journey to becoming a physician-scientist, moments in her career that shaped her fascination with neurology, and how studying human biology at the cellular level can ultimately help improve the lives of patients with cancer.

Dr. Iyad Alnahhas interviews Dr. Danielle Bazer about her and her team's recently published manuscript, entitled: Using a Pre-Radiation Window to Identify Potentially Active Cytotoxic Agents in Adults with Newly Diagnosed Glioblastoma", published online in Neuro-Oncology in November 2024.

Dr. Rachna Malani interviews Drs. Felix Sahm and Arie Perry about their recent manuscript entitled: "cIMPACT-NOW Update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas", published online in Neuro-Oncology in August 2024   Read More

Dr. Iyad Alnahhas interviews Drs. Thomas Zeyen and Johannes Weller about their recent manuscript entitled: "Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ", published online in Neuro-Oncology in October 2024.

Dr. Trisha Larkin is the Director of Pediatric Neuro-Oncology at St. Joseph's Children's Hospital. She is dual-board certified in pediatrics and pediatric hematology-oncology. Dr. Larkin earned her medical degree from Florida International University College of Medicine, followed by a Master of Business Administration in healthcare. She completed her postdoctoral training at Nicklaus Children's Hospital and at the University of Florida Shands Children's Hospital, where she completed a fellowship in pediatric hematology-oncology and bone marrow transplantation. She went on to complete a prestigious advanced fellowship in neuro-oncology at St. Jude Children's Research Hospital in Tennessee. While at St. Jude, she worked on a team of world-renowned physicians to care for children diagnosed with complex brain and spinal tumors. Dr. Larkin is passionate about discovering innovative strategies to improve the care of children with brain tumors and serves as a lead investigator for the Sunshine Project consortium through the National Pediatric Cancer Foundation.  She has been awarded numerous grants for her research in early-phase clinical trials and has authored several peer-reviewed publications in leading oncology journals such as the Journal of Clinical Oncology and Neuro-Oncology. Dr. Larkin has been invited to present her research around the world, including in Germany and Japan.  She serves as associate editor for Neuro-Oncology on the MedNet, an interactive platform for physicians around the world to gather insight about treating complex oncologic diagnoses.  Dr. Larkin is deeply involved in the pediatric cancer community and enjoys volunteering her time to support childhood cancer.for more information on how to be involved go to noraswarriors.com or nationalpcf.org

Send us a textAnd just like that, we have made it to the last episode of the IM Board Review Series! In this episode, we talk about all things neuro-oncology including:Presentation Primary CNS tumors Metastatic Brain TumorsMedical Management of Complications of CNS TumorsParaneoplastic Syndromes Check out our website at www.theneurotransmitters.com to sign up for emails, classes, and quizzes! Would you like to be a guest or suggest a topic? Email us at contact@theneurotransmitters.com Follow our podcast channel on

Dr. Evan Noch interviews Drs. Nathan Leclair, David Raleigh and Olga Anczukow about their recent manuscript entitled: "RNA splicing as a biomarker and phenotypic driver of meningioma DNA methylation groups", published online in Neuro-Oncology in August 2024.  

Dr. Evan Noch interviews Drs. Pravesh Gupta and Krishna Bhat about their recent manuscript entitled "Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas", published online in Neuro-Oncology in August 2024 Read Paper

Patients with newly diagnosed, surgically resected MGMT-unmethylated glioblastoma may benefit from treatment with a therapeutic mRNA vaccine called CVGBM, according to findings from a first-in-human, Phase I safety and dose-escalation study from Tübingen, Germany, reported at the ESMO Congress 2024 held in Barcelona. The CVGBM vaccine encodes multiple molecular features derived from tumor-associated antigens, all of which were judged to be potentially relevant in glioblastoma. After reporting her group’s findings to the ESMO Barcelona meeting, first author Ghazaleh Tabatabai, MD, PhD, a neurologist, Professor of Neuro-Oncology, and Chair of the Department of Neurology and Interdisciplinary Neuro-Oncology at the University Hospital, Tübingen, Germany, talked about the findings with Oncology Times reporter Peter Goodwin.

With a BSc. in molecular biology and an MSc. in physiology, Liz has studied the human body through many lenses. The focus of her PhD program (Pharmacy) is to explore disorders that have directly impacted her life in the world of professional contact sports, and how cannabinoid products could potentially play a role in these.  As a member of the clinical trial team that was recently awarded funding from the NFL to study cannabinoids in concussion and pain, she is excited to bring new data to the literature exploring cannabinoids and athletics. Liz and her team recently published an extensive literature review titled Cannabinoid Therapy in Athletics: A Review of Current Cannabis Research to Evaluate Potential Real‑World Cannabinoid Applications In Sport, which establishes a foundation for their future research.   During our conversation, we discussed:  How Liz became interested in the therapeutic potential of cannabinoids Published literature that supports using cannabinoids for neuroinflammation and neurodegenerative disorders Her team's collaboration with the NFL and ongoing clinical trials focused on neuroinflammation and recovery in athletes, particularly after concussions Current use of cannabis in athletics and how sports organizations are changing their policies  Future directions of research  and more  Thanks to This Episode's Sponsor: The DENT Institute With more than 300,000 patient visits per year, the DENT Neurologic Institute ranks among the largest neuroscience centers in North America. Its 24 subspecialty clinics often treat the most challenging neurologic conditions including but not limited to Migraine, Chronic pain, ALS, MS, Parkinson's, Dementia, and Neuro-Oncology. With their mission of advancing neuroscience, the Dent Institute established a cannabis clinic in 2016 to aid in the treatment of these chronic conditions seen throughout the institute. Learn more at dentinstitute.com Additional Resources Cannabinoid Therapy in Athletics: A Review of Current Cannabis Research to Evaluate Potential Real‑World Cannabinoid Applications In Sport trainwithmaryjane.com Train with Mary Jane on Instagram Submit Your Abstract for CannMed 25 Review the Podcast CannMed Archive

Dr. Iyad Alnahhas interviews Dr. Mulki Mehari about her and her team's recent manuscript entitled: "Enhancing neuro-oncology care through equity-driven applications of artificial intelligence", published online in Neuro-Oncology in August 2024.

In a conversation with CancerNetwork®, Yoshie Umemura, MD, offered various perspectives on progressing in the brain cancer treatment field. In addition to detailing institution-level advances in delivering multidisciplinary care, she highlighted her personal growth as she advanced in the neuro-oncology field while giving key advice to aspiring researchers who are in the early stages of their careers. Umemura, the chief medical officer of the Ivy Brain Tumor Center, division chief of Neuro-Oncology, and the William and Joan Shapiro chair of Neuro-Oncology at Barrow Neurological Institute, first described what drew her to studying neurology and eventually specializing in neuro-oncology, emphasizing the potential to form close connections with patients during treatment. Additionally, her collaborative approach to care and her institution's emphasis on multidisciplinary practice have helped in yielding various accomplishments, which included expediting the development of an investigator-initiated trial during the COVID-19 pandemic. The conversation also focused on the personal aspects of Umemura's neuro-oncology career. Delving into her experiences with immigrating to the United States when she was a high school student, she recalled feeling like an outsider as she learned to speak English and began to study neurology. However, she noted how several role models and mentors in the field have offered her guidance, which helped her grow and take on more leadership positions over time. Continuing to build upon the theme of collaboration in brain cancer research, Umemura emphasized the necessity of finding mentors even outside of one's institution to advance in the field. Additionally, as part of paying it forward to a new generation of neuro-oncologists, researchers should also become open to guiding others once they have gained enough experience.  “When you are at a conference and you meet someone you think you might click with, you're intrigued about, or you're impressed with, you can shoot an email and ask them if they would be open to chatting with you about a question or mentoring you,” Umemura said. “[You should also] pay it forward. Always be open to mentoring others; I think that's the only way to move forward….It [speaks] to the collaborative aspect and how to operate as an outsider. You're not an outsider as long as you make the connection; you can just wedge yourself in.”

On this episode of Health 411, Neuro-Oncologist Dr. Mike Salacz joins host Dr. Jonathan Karp and student producer Marina JB in an engaging conversation about the ups and downs of working with brain and spinal cord tumors.

Treating brain cancers such as glioblastoma can be complex as many of these cancers are difficult to treat and deadly. Soma Sengupta, MD, PhD, MBA, is an accomplished physician-scientist who specializes in brain tumor treatment and research. During this interview, she talks about her innovative research work, including the use of art and music therapy.   About the Author Soma Sengupta, MD, PhD, MBA, is a professor of neurology and vice chair of neurosurgery research at the University of North Carolina, Chapel Hill. She completed her PhD and medical degree at the University of Cambridge, with fellowship training in neuro-oncology and integrative medicine. A physician-scientist with over 90 publications, she is also a creative writer and patient advocate. Dr. Sengupta recently earned an MBA from the University of Cincinnati.

Dr. Maya Graham interviews Drs. Mary Jane Lim-Fat and Kee Kiat Yeo about their recent manuscript entitled "A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients", published online in Neuro-Oncology in July 2024. Link: https://doi.org/10.1093/neuonc/noae142

Dr. Schwartz received his undergraduate and medical degrees from Harvard University, where he graduated Magna Cum Laude. After completing his residency and chief residency in Neurosurgery at The Neurological Institute of NewYork at Columbia-Presbyterian Medical Center, Dr. Schwartz spent a year at Yale-New Haven Medical Center receiving advanced fellowship training. Dr. Schwartz specializes in the surgical treatment of brain tumors, pituitary tumors, and epilepsy using the latest techniques in computer-guided surgical navigation, minimally invasive endoscopy, and microsurgery. Dr. Schwartz was recently named David and Ursel Barnes Professor in Minimally Invasive Surgery, the first endowed professorship in the department.Dr. Schwartz has provided commentary for numerous television shows on ABC, NBC, CBS, and Larry King, in addition to national radio shows. His expertise has been sought through interviews, quoted and published, in the Wall Street Journal, The New York Post, The New York Daily News, and Crain's New York Business; he is asked to lecture throughout the country and world. Dr. Schwartz has published many scholarly articles for the Journal of Neurosurgery, Neurosurgery, Epilepsia, Clinical Neurosurgery the Journal of Neuro-Oncology, Nature Medicine, NeuroImage and the Journal of Neuroscience.Dr. Schwartz has been named one of New York's Super Doctors, Best Doctors in New York Magazine, America's Top Surgeons, America's Best Doctors and America's Best Doctors for Cancer. He is the co-author of two books on endoscopic skull base surgery and endoscopic pituitary surgery.

Dr. Iyad Alnahhas interviews Dr. Linda Bi, Hia Ghosh and Ruchit Patel about their recent manuscript entitled: "Contemporary Prognostic Signatures and Refined Risk Stratification of Gliomas: An Analysis of 4400 Tumors", published online in Neuro-Oncology in August 2024. More Information: https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noae164/7737688

Send us a Text Message.Meet Simon Khagi, MD, Medical Director of Neuro-Oncology at Hoag Family Cancer Institute and a triple-board-certified oncologist.  He specializes in primary brain, spine, lung, and advanced skin cancers and has extensive experience with glioblastoma, astrocytoma, oligodendroglioma, meningioma, ependymoma, medulloblastoma, brain metastases, and rare brain tumors.  

Dr. Iyad Alnahhas interviews Drs. Minyoung Oh and Hyungwoo Cho about their recent manuscript entitled: "Enhancing Prognostication and Treatment Response Evaluation in Primary CNS Lymphoma with 18F-FDG PET/CT", published online in Neuro-Oncology in August 2024.   Link to manuscript

Join Dr. Sanjay Juneja as he talks with Dr. Sam Blackman about advancements in Pediatric Neuro-Oncology. Dr. Blackman shares his journey from philosophy to medicine, discusses innovative treatments for pediatric brain cancer, and explores the role of AI in neuro-oncology. Discover insights into the latest therapies and the future of brain cancer treatment for children in this episode. Gain a deeper understanding of the challenges and breakthroughs in treating pediatric brain tumors.

Dr. Jasmin Jo interviews Dr. Monika Hegi about her and her team's recent manuscript entitled: "No benefit from TMZ treatment in GB with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly GB patients", published online in Neuro-Oncology in (I will fill in through Libsyn)

Dr. Maya Graham interviews Dr. Martin van den Bent about his and his team's recent review article entitled "The biological significance of age, enhancement, extent of resection and tumor grade in IDH mutant gliomas: how should they inform treatment decision in the era of IDH inhibitors? Invited review", published online in Neuro-Oncology in

 Dr. John Fortunato interviews Dr. Adrienne Boirre about her and her team's recent manuscript entitled "Leptomeningeal metastases from solid tumors: A SNO and ASCO consensus review on clinical management and future directions", published online in Neuro-Oncology on 

Dr. Iyad Alnahhas interviews Drs. Justin Lathia and Marco Gallo about their recent manuscript entitled "Cancer stem cell hypothesis 2.0 in glioblastoma: where are we now and where are we going?", published online in Neuro-Oncology in May 2024.

Dr. Ankush Bhatia interviews Dr. Keaton Piper about his and his team's manuscript, entitled "Consensus Review on Strategies to Improve Delivery Across the BBB Including Focused Ultrasound", published online in Neuro-Oncology in May 2024 Read Paper

Dr. Evan Noch interviews Dr. Gunther Nussbaumer about his recent paper entitled: "Gliomatosis cerebri in children: a poor prognostic phenotype of diffuse gliomas with a distinct molecular profile" published online in Neuro-Oncology in May 2024.

Dr. Maya Graham interviews Drs. Josephine Hendriksen and Joachim Weischenfeldt about their recent manuscript, "Immunotherapy drives mesenchymal tumour cell state shift and TME immune response in glioblastoma patients," published online in Neuro-Oncology in May 2024.

The May 2024 replay features four episodes on neuro-oncology for brain cancer awareness month. The episode begins with Dr. Philipp Karschnia discussing the assessment of whether MTHFR polymorphisms affect the risk for leukoencephalopathy. The episode continues with Dr. Ingo Mellinghoff discussing new treatment opinions for isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas. The third interview leads into a conversation with Dr. Linda Liau on the study of vaccine-based therapy for GBM. The episode concludes with Dr. Teddy Totimeh talking about brain tumor programs in Asia and Africa. Podcast Links: MTHFR Polymorphisms and Leukoencephalopathy Risk in CNS Lymphoma Patients   New Treatment for IDH mt Gliomas  Study of Vaccine-Based Therapy for GBM Brain Tumor Programs in Asia and Africa  Article Links: https://doi.org/10.1212/WNL.0000000000207670  https://www.nejm.org/doi/full/10.1056/NEJMoa2304194 https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847 https://doi.org/10.1016/j.wneu.2023.04.067 Disclosures can be found at Neurology.org.

About our guest … Dr. Lasky joined the Cure the Kids Foundation in 2017. He attended medical school at the University of Illinois in Chicago and did his pediatric residency at the University of Chicago. He completed his Pediatric Hematology Oncology fellowship at UCLA in 2006 and was director of the Pediatric Neuro-Oncology Program at UCLA until 2009 when he moved to Harbor-UCLA Medical Center in Torrance, CA, and was named Chief of the Division of Pediatric Hematology Oncology. While there, Dr. Lasky became involved with a number of clinical trials for patients with bleeding disorders (including hemophilia and von Willebrand disease) as well as sickle cell anemia. While continuing to have research interests in pediatric brain tumors and immunology, he also is interested in running and developing clinical trials for patients with bleeding disorders and sickle cell anemia. Dr. Lasky is a member of several professional societies including the Children's Oncology Group, Society for Neuro-Oncology, the American Society of Hematology, and the American Academy of Pediatrics. He enjoys watching sports, reading, music, and outdoor activities with his family. In September of 2022, Dr. Lasky is now the Medical Director at Cure 4 The Kids (C4K).

What I learned (or relearned?) at HOPA's 2024 Annual Conference: updates in Neuro Oncology, fedratinib toxicity, and bispecific antibodies in multiple myeloma. Also, fam-trastuzumab deruxtecan (T-DXd) garnered a site-agnostic approval for HER2 amplified solid tumors. Finally, the ALINA study, adjuvant alectinib in ALK+ NSCLC, was published in this week's NEJM.